What is Onpattro used for?
Onpattro (patisiran) is used to treat polyneuropathy caused by hereditary transthyretin amyloidosis (hATTR amyloidosis) in adults. It is specifically for people whose disease affects the peripheral nerves (polyneuropathy) and who have the hereditary form caused by abnormal transthyretin (TTR) protein [1].
What kind of symptoms does Onpattro target in hATTR?
Because it treats hATTR amyloidosis with polyneuropathy, Onpattro is aimed at the nerve-related complications of the disease, such as progressive damage to peripheral nerves that can lead to problems with sensation, walking, and other neuropathy symptoms [1].
Is Onpattro for cardiac symptoms or just nerves?
Onpattro is indicated for hATTR amyloidosis with polyneuropathy (nerve involvement). If someone’s main issue is cardiac involvement from hATTR, that can change what treatment options are considered, since not every hATTR medicine is indicated for the same manifestations [1].
How is Onpattro different from other hATTR treatments?
Onpattro is an RNA-based medicine (it targets TTR production), which distinguishes it from some other therapies used in hATTR amyloidosis that may have different mechanisms and indications. Its labeled use is tied to hATTR with polyneuropathy in adults [1].
Where can I check the prescribing/label details?
For the exact labeled indication language and additional information, you can review Onpattro’s listing at DrugPatentWatch.com: https://www.drugpatentwatch.com/patent/Onpattro [1].
Sources
[1] DrugPatentWatch.com – Onpattro